Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
    • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Always Search for Ways to Connect With Patients
    Oncology nurse-patient relationship
    Always Search for Ways to Connect With Patients
    September 18, 2020
    Word Choice Matters When Caring for Patients With Cancer
    Patient empowerment
    Word Choice Matters When Caring for Patients With Cancer
    September 11, 2020
    Learning in the Face of Adversity: Nurse Residency and COVID-19
    COVID-19
    Learning in the Face of Adversity: Nurse Residency and COVID-19
    September 04, 2020
    Bedside Nurses Bring Value to Ethical Consults
    Ethics in nursing
    Bedside Nurses Bring Value to Ethical Consults
    August 14, 2020
    What’s Working and What Isn’t in Telemedicine
    Oncology nurse education
    What’s Working and What Isn’t in Telemedicine
    July 31, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    Oncology Drug Reference Sheet: Panitumumab (Vectibix®)
    Prescription medication

    Oncology Drug Reference Sheet: Panitumumab

    Approved in 2006 as monotherapy for the treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC) after disease progression following treatment, panitumumab has been a mainstay metastatic disease for more than a decade. In 2014, it received additional indication as first-line therapy for the treatment of patients with EGFR-expressing mCRC in combination with FOLFOX, but in 2017, use was narrowed to wild-type RAS (not mutated RAS). 

    March 23, 2020
    Oncology Drug Reference Sheet: Venetoclax
    Treatments

    Oncology Drug Reference Sheet: Venetoclax

    Venetoclax (Venclexta®) was approved by the U.S. Food and Drug Administration on May 15, 2019, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as a single agent or in combination therapy. Previously, it had been approved in late 2018 for use in combination therapy for acute myeloid leukemia (AML) in older adults or those with significant comorbidities.

    August 27, 2019
    How ONS Is Supporting ONNs’ Professional Development
    Nurse navigator

    How ONS Is Supporting ONNs’ Professional Development

    Professional development needs of oncology nurse navigators (ONNs) have not been clearly identified, both for novice and more experienced navigators. Although some work has begun to define training for novice ONNs, most information about education for experienced ONNs comes from evaluation data and anecdotal reports.    

    May 28, 2019
    Joint Commission Focuses on Quality, Safety for 2019
    Safety

    Joint Commission Focuses on Quality, Safety for 2019

    As part of its ongoing work “to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating healthcare organizations and inspiring them to excel in providing safe and effective care of the highest quality and value,” the Joint Commission hosts an annual Health Care Association Forum to educate associations about the commission’s latest initiatives and goals. Here are the outcomes that affect nursing practice in 2019.

    March 27, 2019
    Oncology Drug Reference Sheet: Glasdegib
    U.S. Food and Drug Administration (FDA)

    Oncology Drug Reference Sheet: Glasdegib

    In November 2018, the U.S. Food and Drug Administration (FDA) approved glasdegib (Daurismo™) for use in combination with low-dose cytarabine for treatment of patients with newly diagnosed acute myeloid leukemia who are not eligible for intensive chemotherapy. Data from clinical trials indicated that the regimen is safe for older adults and those with significant comorbidities, such as cardiac disease, poor performance status, or elevated serum creatinine.

    March 26, 2019
    Oncology Nurse Navigator
    Nurse navigator

    Updated Competencies Outline Oncology Nurse Navigator Role From Novice to Expert

    Based on the results of the oncology nurse navigator (ONN) role delineation survey and feedback from ONS membership, ONS evaluated and updated its ONN Core Competencies. Several significant changes were made.

    May 19, 2017

    To discuss the information in this article with other oncology nurses, visit the ONS Communities.

    To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

    Barbara Lubejko RN, MS
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap

  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
    • © Copyright 2020 Oncology Nursing Society
     
    Back to Top ▲